Cancer Discov. 2023 Aug 4;13(8):1752-1753. doi: 10.1158/2159-8290.CD-NB2023-0045.
The final overall survival (OS) results for the ADAURA trial show that osimertinib reduces the risk of death by 51% in patients with EGFR-mutated non-small cell lung cancer. For stage II or IIIA disease, the 5-year OS was 85% in patients who received osimertinib and 73% in the control group. The findings were nearly identical when patients with stage IB tumors were included in the analysis.
ADAURA 试验的最终总生存（OS）结果显示，奥希替尼可将 EGFR 突变型非小细胞肺癌患者的死亡风险降低 51%。对于 II 期或 IIIA 期疾病，接受奥希替尼治疗的患者 5 年 OS 为 85%，而对照组为 73%。当将 IB 期肿瘤患者纳入分析时，结果几乎相同。
